Boehringer Ingelheim (BI), a German pharmaceutical company, has entered into a partnership with Canada’s Phenomic AI to leverage the latter’s single-cell transcriptomics platform for the discovery of drug targets in stroma-rich cancers, including colorectal and pancreatic tumors. In return for the option to license the identified targets and secure development and commercialization rights, BI will provide Phenomic AI with approximately USD 9 million in upfront and near-term payments, along with over USD 500 million in potential milestone payments and royalties.
Tumor stroma consists of tissues that support the growth and metastasis of cancer while shielding malignant cells from therapeutic interventions, making the associated neoplasms a significant contributor to cancer-related mortality.- Flcube.com
